111
YI111 in brief
111 is a listed company in the Retail - Pharmacy industry, based in China. It was founded in 2010. Its market value was $32 M on 1 August 2026, which makes it the 22,804th largest listed company in the world and the 4,199th largest in China on this site. In the year to December 2025 it had sales of $1.8 B and a net loss of $3 M. Its largest product and service lines by sales in 2025 were B2B segment (98%), Drugs (93%) and Nutritional supplements (3%). Its shares trade under the symbol YI (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About 111
We face various legal and operational risks as a company based in and primarily operating in China. The PRC government has significant authority to exert influence on the ability of a China-based company, like us, to conduct its business, accept foreign investments or be listed on a U.S. stock exchange. For example, we face risks associated with regulatory approvals of offshore securities offerings, anti-monopoly regulatory investigations and actions, cybersecurity and data privacy compliance. The PRC government may also exert influence on our operations as it deems appropriate to further regulatory, political and societal goals. The PRC government has recently published new policies that affected our industry and we cannot rule out the possibility that it will in the future further release regulations or policies regarding our industry that could adversely affect our business, financial condition and results of operations. Any such action, once taken by the PRC government, could cause the value of such securities to significantly decline or in extreme cases, become worthless.
From the company's annual report filed with the US SEC: read the report
111 timeline
- 2010
- 🏁· approximateFounded
- 2018
- 🔔· approximateInitial public offering on Nasdaq
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2020
- 💰Revenue passed $1 billionFY2020 revenue of $1.3 billion, up from $568 million in FY2019.
- 2023
- 💰Record revenue of $2.1 billionFY2023, the highest of the 8 years on record.
Events of 111 from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in China: #2,609 (Jan 2020) · #2,847 (Jan 2021) · #4,611 (Jan 2022) · #4,665 (Dec 2022) · #4,751 (Jul 2023) · #5,024 (Jan 2024) · #4,453 (Mar 2026) · #4,220 (Aug 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 0.0×
- Price / book
- —
- Free cash flow yield
- 51.2%
- Net margin (TTM)
- -0.2%
- Operating margin
- -0.0%
- Return on equity
- —
- Liabilities / assets
- 90.3%
- Revenue growth
- -9.0%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1.8B | -9.0% | $-0M | $-3M | -0.2% |
| Dec 2024 | $2.0B | -6.3% | $0M | $-3M | -0.1% |
| Dec 2023 | $2.1B | +7.4% | $-49M | $-50M | -2.4% |
| Dec 2022 | $2.0B | +0.5% | $-54M | $-55M | -2.8% |
| Dec 2021 | $1.9B | +55.1% | $-101M | $-97M | -5.0% |
| Dec 2020 | $1.3B | +121.5% | $-73M | $-72M | -5.7% |
| Dec 2019 | $568M | +118.5% | $-71M | $-72M | -12.7% |
| Dec 2018 | $260M | — | $-58M | $-56M | -21.4% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $17M | $1M | $16M | $-0.05 | — |
| Dec 2024 | $36M | $2M | $34M | $-0.05 | — |
| Dec 2023 | $-63M | $1M | $-64M | $-0.33 | — |
| Dec 2022 | $-3M | $5M | $-8M | $-0.36 | — |
| Dec 2021 | $-108M | $10M | $-118M | $-0.63 | — |
| Dec 2020 | $-18M | $4M | $-22M | $-0.42 | — |
| Dec 2019 | $-74M | $3M | $-76M | $-0.44 | — |
| Dec 2018 | $-50M | $2M | $-52M | $-0.56 | — |
SEC filings
- Oct 26, 20266-KReport of foreign issuer
- Sep 28, 20266-KReport of foreign issuer
- Sep 17, 20266-KReport of foreign issuer
- Sep 17, 20266-KReport of foreign issuer
- Jun 4, 20266-KReport of foreign issuer
- Apr 30, 202620-FAnnual report (foreign issuer) · period to Dec 2025
- Apr 9, 20266-KReport of foreign issuer
- Dec 17, 20256-KReport of foreign issuer
- Sep 17, 20256-KReport of foreign issuer
- Aug 29, 202520-F/AAnnual report (foreign issuer, amended) · period to Dec 2024
- Jun 20, 20256-KReport of foreign issuer
- Apr 29, 202520-FAnnual report (foreign issuer) · period to Dec 2024
Official filings of 111 with the US Securities and Exchange Commission.
Annual results
- Revenue
- $1.8 B
- Operating income
- $-0 M
- Net income
- $-3 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $315 M
- Total liabilities
- $284 M
- Total equity
- $-100 M
As of December-2025
Top 11 institutional investors in 111#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Citadel Advisors LLC | 26,260 | +8,921 (+51.45%) | 0.30% | $0 M | Nov 16, 2026 |
| 2 | Renaissance Technologies LLC | 12,714 | -200 (-1.55%) | 0.15% | $0 M | Nov 12, 2026 |
| 3 | Serenus Wealth Advisors, LLC | 3,977 | -343 (-7.94%) | 0.05% | $0 M | Nov 10, 2026 |
| 4 | UBS Group AG | 1,477 | -120 (-7.51%) | 0.02% | $0 M | Nov 10, 2026 |
| 5 | Nuveen, LLC | 599 | New | 0.01% | $0 M | Nov 10, 2026 |
| 6 | Citigroup Inc | 531 | New | 0.01% | $0 M | Nov 4, 2026 |
| 7 | SBI Securities Co., Ltd. | 149 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 8 | Morgan Stanley | 113 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 9 | Jpmorgan Chase & Co | 71 | +24 (+51.06%) | 0.00% | $0 M | Nov 12, 2026 |
| 10 | Strategic Financial Concepts, LLC | 30 | New | 0.00% | $0 M | Nov 16, 2026 |
| 11 | Rhumbline Advisers | 22 | 0 (0.00%) | 0.00% | $0 M | Nov 10, 2026 |
Mutual funds holding 111#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 2,444 | $0 M | — | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of May 31, 2026. The 1 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at 111#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Yang Luke ChenDirector | Sell | -38,120 | 0.180 | 7 Klocal | 413,342 | Form 4 |
| filed | Yang Luke ChenDirector | Sell | -44,000 | 0.180 | 8 Klocal | 451,462 | Form 4 |
| filed | Yang Luke ChenDirector | Sell | -44,000 | 0.180 | 8 Klocal | 451,462 | Form 4 |
| filed | Yang Luke ChenDirector | Sell | -44,000 | 0.230 | 10 Klocal | 495,462 | Form 4 |
| filed | Yang Luke ChenDirector | Sell | -44,000 | 0.230 | 10 Klocal | 495,462 | Form 4 |
| filed | Yang Luke ChenDirector | Sell | -44,000 | 0.230 | 10 Klocal | 495,462 | Form 4 |
| filed | Jian David SunDirector | Sell | -58,800 | 0.230 | 14 Klocal | 413,211 | Form 4 |
| filed | Yang Luke ChenDirector | Sell | -49,920 | 0.230 | 11 Klocal | 539,462 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals. This company files with the SEC as a foreign issuer; its insiders often report prices in the home currency, so amounts are as filed and not converted to dollars
Markets and events: 111#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 2-for-1 split
Trading halts
- 2026-09-10 18:32 UTC, code LUDP, resumed 18:37 UTC
- 2026-09-08 13:49 UTC, code LUDP, resumed 13:59 UTC
- 2026-08-31 17:57 UTC, code LUDP, resumed 18:02 UTC
- 2026-01-30 20:34 UTC, code LUDP, resumed 20:39 UTC
- 2026-01-30 20:09 UTC, code LUDP, resumed 20:29 UTC
Fails to deliver
- : 324 shares at $2.85
- : 3,734 shares at $3.83
- : 3,157 shares at $3.76
- : 802 shares at $3.42
- : 1,407 shares at $3.33
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
111 scorecard#
Passes 6 of the 15 checks that could be worked out: strongest in profitability (2 of 4), weakest in growth (1 of 6). Fiscal year 2025; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth1 of 6
- ✗Revenue grew in the newest year-9.0%Revenue down 9.0% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-2.9%-2.9% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-2.9%-2.9% a year against Retail - Pharmacy's median of 0.4% (6 companies).
- ✗Earnings per share grew in the newest year-0.05 vs -0.05Diluted EPS -0.05 in fiscal 2025 against -0.05 the year before (report's currency).
- ✓Net income higher than five years earlier-$3 M-$3 M in fiscal 2025 against -$72 M in 2020.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
Profitability2 of 4
- ✗Profitable in the newest year-$3 MNet income -$3 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median-0.0%-0.0% against Retail - Pharmacy's median of -2.4% (7 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-0.0%-0.0% in fiscal 2025 against -2.7% in 2022.
Financial health2 of 4
- ✓Short-term assets cover short-term liabilities1.1×Current ratio 1.09 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-0.1×Operating income -0.1 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years2 of 3Positive in 2 of the three years to fiscal 2025.
- ✓Altman Z-score outside the distress zone3.35Z-score 3.35 (safe zone) for fiscal 2025.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year1.3%Diluted shares up 1.3% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Retail - Pharmacy, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from 111's statements, beside the median of Retail - Pharmacy.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -0.0% | -2.4% | |
| Net margin | -0.2% | -1.4% | |
| Revenue growth, 3 years a year | -2.9% | 0.4% | |
| Revenue growth | -9.0% | 8.3% | |
| Free cash flow margin | 0.9% | -0.3% |
4of 8on the Piotroski tests of financial strength
- Revenue fell 9.0% against the year before.
- Net loss of $3 million, the 10th loss-making year in a row.
- Shareholders' equity is negative: -$100 million.
- Operating income covers the interest bill only -0.1 times.
111: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in CNY millions; per-share figures in CNY; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 12,556−12.8%100% | 14,401−3.7%100% | 14,948+10.6%100% | 13,517+8.8%100% | 12,426+51.5%100% | 8,203+108%100% | 3,952+121%100% | 1,786+86.1%100% | 959+9.8%100% | 874—100% | |
| Cost of revenue | 11,833−12.8%94.2% | 13,572−3.7%94.2% | 14,099+11.2%94.3% | 12,677+7.4%93.8% | 11,805+50.6%95.0% | 7,837r227+107%95.5% | 3,787r129+5022%95.8% | 74+32.3%4.1% | 56—5.8% | — | |
| Gross profit | 723−12.8%5.8% | 829−2.3%5.8% | 849+1.1%5.7% | 840+35.2%6.2% | 621+69.8%5.0% | 366+121%4.5% | 165r143+58.4%4.2% | 104r89+29.5%5.8% | 80+8.6%8.4% | 74—8.5% | |
| Selling and marketing | 259−17.6%2.1% | 314−30.0%2.2% | 448−2.1%3.0% | 458−10.8%3.4% | 513+28.4%4.1% | 400+17.3%4.9% | 341+31.0%8.6% | 260+36.8%14.6% | 190−24.8%19.8% | 253—28.9% | |
| General and administrative | 69−2.0%0.6% | 71−68.4%0.5% | 224+9.0%1.5% | 206−0.7%1.5% | 207+61.4%1.7% | 128+3.8%1.6% | 124+25.1%3.1% | 99+84.8%5.5% | 53−12.2%5.6% | 61—7.0% | |
| Total costs and expenses | 12,558−12.8%100% | 14,399−5.9%100.0% | 15,298+10.2%102% | 13,888+6.3%103% | 13,068+50.6%105% | 8,676+95.2%106% | 4,446+103%112% | 2,186+80.2%122% | 1,214−2.0%126% | 1,238—142% | |
| Operating income | −2.4−212%−0.0% | 2.1—0.0% | −350—−2.3% | −371—−2.7% | −642—−5.2% | −473—−5.8% | −494—−12.5% | −400—−22.4% | −254—−26.5% | −364—−41.7% | |
| Interest and finance income | 3.9−44.8%0.0% | 7.0−20.3%0.0% | 8.8+8.8%0.1% | 8.1−17.0%0.1% | 9.8+54.9%0.1% | 6.3+31.4%0.1% | 4.8+10.3%0.1% | 4.4+8.4%0.2% | 4.0+73.9%0.4% | 2.3—0.3% | |
| Interest expense and finance costs | 36+25.6%0.3% | 28+40.7%0.2% | 20+49.8%0.1% | 13+145%0.1% | 5.5−37.8%0.0% | 8.8+143%0.1% | 3.6—0.1% | — | 0.1−92.7%0.0% | 0.8—0.1% | |
| Provision for credit losses | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | — | — | — | |
| Other non-operating income (expense) | 11—0.1% | −0.6−108%−0.0% | 7.6−6.4%0.1% | 8.1−45.4%0.1% | 15+371%0.1% | 3.2+279%0.0% | 0.8−92.8%0.0% | 12+173%0.6% | 4.2—0.4% | −3.4—−0.4% | |
| Income before tax | −23—−0.2% | −21—−0.1% | −353—−2.4% | −376—−2.8% | −621—−5.0% | −467—−5.7% | −502—−12.7% | −382—−21.4% | −249—−26.0% | −363—−41.6% | |
| Income tax | 0.0−86.5%0.0% | 0.1−61.8%0.0% | 0.3—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0−100%0.0% | 0.0—0.0% | — | — | |
| Net income including minority interests | −23—−0.2% | −21—−0.1% | −353—−2.4% | −376—−2.8% | −621—−5.0% | −467—−5.7% | −502—−12.7% | −382—−21.4% | −249—−26.0% | −363—−41.6% | |
| Minority interests' share of net income | −4.1—−0.0% | −8.4—−0.1% | −17—−0.1% | −15—−0.1% | −28—−0.2% | 0—0.0% | −2.2—−0.1% | −2.0—−0.1% | −0.7—−0.1% | −0.8—−0.1% | |
| Net income attributable to shareholders | — | — | — | — | — | — | — | −382—−21.4% | −249—−26.0% | −363—−41.6% | |
| Earnings per share, basic | -0.38—— | -0.38—— | -2.33—— | -2.50—— | -4.04—— | -2.77—— | -3.05—— | -3.82—— | -3.45—— | -5.81—— | |
| Earnings per share, diluted | -0.38—— | -0.38—— | -2.33—— | -2.50—— | -4.04—— | -2.77—— | -3.05—— | -3.82—— | -3.45—— | -5.81—— | |
| Shares, weighted average (basic) | 174+1.3%— | 172+1.9%— | 169+1.2%— | 167+0.5%— | 166+0.7%— | 165+0.7%— | 164—— | — | — | — | |
| Shares, weighted average (diluted) | 174+1.3%— | 172+1.9%— | 169+1.2%— | 167+0.5%— | 166+0.7%— | 165+0.7%— | 164+64.6%— | 99+38.1%— | 720.0%— | 72—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 511+10.5%23.2% | 462−23.4%16.6% | 604−10.4%19.5% | 674+1.9%19.4% | 661−44.4%21.0% | 1,190+105%39.3% | 581−31.9%36.1% | 854+409%55.2% | 168−55.1%22.0% | 374—— | |
| Short-term investments | 50—2.3% | — | 50−75.6%1.6% | 206+12.8%5.9% | 183−39.2%5.8% | 300—9.9% | — | 253−13.9%16.3% | 294—38.5% | — | |
| Receivables | 260−37.1%11.8% | 413−23.0%14.8% | 537+9.8%17.4% | 489+20.9%14.1% | 404+148%12.9% | 163+150%5.4% | 65+128%4.1% | 29+40.1%1.8% | 20−28.1%2.7% | 28—— | |
| Inventory | 998−28.0%45.4% | 1,387−2.3%49.8% | 1,419−5.3%45.9% | 1,499+33.7%43.1% | 1,121+46.3%35.6% | 767+57.6%25.3% | 486+131%30.2% | 211+46.4%13.6% | 144—18.9% | — | |
| Other current assets | 17+146%0.8% | 6.8r252−97.0%0.2% | 226−19.9%7.3% | 282+16.5%8.1% | 242−22.3%7.7% | 312+49.5%10.3% | 209+29.4%13.0% | 161+53.7%10.4% | 105—13.7% | — | |
| Current assets | 2,125−19.8%96.6% | 2,650−9.7%95.0% | 2,933−9.3%95.0% | 3,236+15.5%93.1% | 2,802−2.5%89.1% | 2,873+93.9%94.9% | 1,481−1.7%92.0% | 1,507+106%97.5% | 730—95.7% | — | |
| Property, plant and equipment | 21−35.8%1.0% | 33−4.2%1.2% | 34−29.2%1.1% | 48−39.6%1.4% | 80+84.8%2.6% | 43+45.6%1.4% | 30+47.0%1.9% | 20+19.2%1.3% | 17—2.2% | — | |
| Right-of-use (leased) assets | 44−50.5%2.0% | 89−14.2%3.2% | 104−36.7%3.4% | 164−29.9%4.7% | 234+137%7.4% | 99+12.3%3.3% | 88—5.5% | — | — | — | |
| Other intangible assets | 0.9−39.6%0.0% | 1.4−36.3%0.1% | 2.3−30.9%0.1% | 3.3−33.4%0.1% | 4.9−24.7%0.2% | 6.5−18.8%0.2% | 8.0+78.1%0.5% | 4.5−5.2%0.3% | 4.8—0.6% | — | |
| Long-term investments | — | — | 2.00.0%0.1% | 2.0−33.3%0.1% | 3.0+2043%0.1% | 0.10.0%0.0% | 0.1−98.7%0.0% | 110.0%0.7% | 11—1.5% | — | |
| Total assets | 2,200−21.1%100% | 2,788−9.8%100% | 3,089−11.1%100% | 3,474+10.4%100% | 3,146+3.9%100% | 3,026+87.9%100% | 1,610+4.1%100% | 1,546+103%100% | 763—100% | — | |
| Accounts payable | 1,282−25.5%58.3% | 1,721+8.4%61.7% | 1,589−10.0%51.4% | 1,765+31.0%50.8% | 1,347+25.5%42.8% | 1,073+142%35.5% | 444+109%27.6% | 212+65.6%13.7% | 128—16.8% | — | |
| Current liabilities | 1,954−16.6%88.8% | 2,343−14.7%84.0% | 2,745+0.7%88.9% | 2,725+27.9%78.4% | 2,130+30.7%67.7% | 1,630+111%53.8% | 773+146%48.0% | 315+56.4%20.3% | 201—26.4% | — | |
| Lease liabilities (non-current) | 30−46.0%1.4% | 55−11.5%2.0% | 63−37.7%2.0% | 100−39.3%2.9% | 166+165%5.3% | 62+9.4%2.1% | 57—3.5% | — | — | — | |
| Total liabilities | 1,986−17.5%90.3% | 2,407−14.4%86.3% | 2,813−0.4%91.1% | 2,826+23.0%81.3% | 2,297+35.5%73.0% | 1,696+103%56.0% | 836+159%51.9% | 323+60.4%20.9% | 201—26.4% | — | |
| Retained earnings | −3,950—−180% | −3,884—−139% | −3,819—−124% | −3,427—−98.6% | −3,010—−95.7% | −2,340—−77.3% | −1,883—−117% | −1,384—−89.5% | −1,004—−131% | — | |
| Shareholders' equity | −702—−31.9% | −643—−23.1% | −583—−18.9% | −415—−11.9% | −173−148%−5.5% | 357−54.0%11.8% | 777−36.6%48.2% | 1,224—79.2% | −946—−124% | — | |
| Minority interests | −19—−0.9% | −16—−0.6% | −11−291%−0.4% | 5.9−72.2%0.2% | 21−56.8%0.7% | 49—1.6% | −2.7—−0.2% | −0.5−136%−0.0% | 1.4—0.2% | — | |
| Total equity | −721—−32.8% | −658—−23.6% | −595—−19.3% | −409—−11.8% | −152−137%−4.8% | 406−47.5%13.4% | 774−36.8%48.1% | 1,224—79.1% | −945—−124% | −688—— | |
| Total liabilities and equity | 2,200−21.1%100% | 2,788−9.8%100% | 3,089−11.1%100% | 3,474+10.4%100% | 3,146+3.9%100% | 3,026+87.9%100% | 1,610+4.1%100% | 1,546+103%100% | 763—100% | — | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 12−30.2%0.1% | 17−22.1%0.1% | 22−46.6%0.1% | 41+50.0%0.3% | 27+94.2%0.2% | 14+20.1%0.2% | 12+3.6%0.3% | 11−24.0%0.6% | 15+22.9%1.5% | 12—1.4% | |
| Share-based compensation | 10−50.1%0.1% | 20−91.1%0.1% | 227+39.9%1.5% | 162+11.3%1.2% | 146+92.3%1.2% | 76+39.5%0.9% | 54+5.7%1.4% | 51+418%2.9% | 9.9+189%1.0% | 3.4—0.4% | |
| Cash from operating activities | 119−54.7%0.9% | 263—1.8% | −447—−3.0% | −23—−0.2% | −689—−5.5% | −117—−1.4% | −512—−13.0% | −343—−19.2% | −204—−21.3% | −389—−44.5% | |
| Capital expenditure | −4.5—−0.0% | −15—−0.1% | −9.8—−0.1% | −32—−0.2% | −63—−0.5% | −26—−0.3% | −20—−0.5% | −14—−0.8% | −6.8—−0.7% | −5.3—−0.6% | |
| Intangible assets bought | — | — | −0.0—−0.0% | −0.1—−0.0% | −0.1—−0.0% | −0.3—−0.0% | −4.6—−0.1% | −0.4—−0.0% | −0.1—−0.0% | −1.6—−0.2% | |
| Cash from investing activities | −54−244%−0.4% | 37−75.4%0.3% | 152—1.0% | −47−178%−0.3% | 60—0.5% | −325−237%−4.0% | 238+435%6.0% | 44—2.5% | −36—−3.8% | −268—−30.6% | |
| Debt repaid | — | — | — | −250—−1.8% | −15—−0.1% | — | — | — | — | — | |
| Shares issued | 0.7+5221%0.0% | 0.0−93.7%0.0% | 0.2−18.6%0.0% | 0.3−90.6%0.0% | 2.9−53.9%0.0% | 6.3−44.2%0.1% | 11—0.3% | — | 0.0+2400%0.0% | 0.0—0.0% | |
| Shares bought back | — | — | — | — | −5.9—−0.0% | −12—−0.1% | −23—−0.6% | — | — | — | |
| Cash from financing activities | −21—−0.2% | −406−297%−2.8% | 206+806%1.4% | 23−69.4%0.2% | 74−93.1%0.6% | 1,070+882%13.0% | 109−88.8%2.8% | 973+1865%54.5% | 50−66.6%5.2% | 148—17.0% | |
| Exchange-rate effect on cash | — | — | — | — | −3.5—−0.0% | −8.1−184%−0.1% | 9.7−18.8%0.2% | 12—0.7% | −15−142%−1.5% | 35—4.0% | |
| Change in cash | 43—0.3% | −105—−0.7% | −93—−0.6% | −44—−0.3% | −558−190%−4.5% | 621—7.6% | −156−123%−3.9% | 686—38.4% | −206—−21.5% | −472—−54.1% | |
| Report | 20-F | 20-F | 20-F | 20-F/A | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What 111 sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Product(total)$1.7 B99%-13%
- B2B segment$1.7 B98%-13%
- Drugs$1.6 B93%-13%
- Nutritional supplements$60 M3.5%-21%
- Other products$33 M1.9%+16%
- B2C segment$31 M1.8%-14%
- Medical supplies and devices$21 M1.2%+5.7%
- Service(total)$12 M0.7%-20%
- MP Service$8 M0.5%-13%
- Other Services$4 M0.2%-30%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
How 111 compares in Retail - Pharmacy
- Market cap$32 M · higher than 12% of 35
- Revenue$1.8 B · higher than 35% of 38
- Net margin-0.2% · higher than 23% of 36
- Revenue growth-9.0% · higher than 20% of 11
- Price / sales0.0× · lowest of 25
- FCF yield51.3% · highest of 5
Peer comparison · Retail - Pharmacy
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| 111🇨🇳 | $32 M | — | -0.2% | -9.0% |
| Tsuruha Holdings Inc.🇯🇵 | $6.9 B | 23.8× | 2.9% | — |
| Alibaba Health Information Technology Limited🇭🇰 | $6.7 B | 24.0× | 5.7% | — |
| Matsumotokiyoshi Holdings🇯🇵 | $6.2 B | 16.5× | 5.0% | — |
| Yifeng Pharmacy Chain Co., Ltd.🇨🇳 | $4.3 B | 17.8× | 6.9% | — |
| Raia Drogasil S.A.🇧🇷 | $4.1 B | 16.8× | 2.9% | — |
| Selçuk Ecza Deposu Ticaret Ve Sanayi A.S.🇹🇷 | $3.7 B | 72.7× | 3.5% | — |
| Sugi Holdings Co., Ltd.🇯🇵 | $3.3 B | 23.6× | 3.1% | — |
| Cosmos Pharmaceutical Corporation🇯🇵 | $3.3 B | 19.5× | 3.1% | — |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at 111? Verify and update this profile — free
Show 111's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.